

Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma

Smruthy Sivakumar^{1,2}, F. Anthony San Lucas¹, Tina L. McDowell³, Wenhua Lang³, Li Xu³, Junya Fujimoto³, Jianjun Zhang⁴, P. Andrew Futreal⁵, Junya Fukuoka⁶, Yasushi Yatabe⁷, Steven M. Dubinett⁸, Avrum E. Spira⁹, Jerry Fowler¹, Ernest T. Hawk¹⁰, Ignacio I. Wistuba³, Paul Scheet^{1,2}, and Humam Kadara^{1,11}



Abstract

There is a dearth of knowledge about the pathogenesis of premalignant lung lesions, especially for atypical adenomatous hyperplasia (AAH), the only known precursor for the major lung cancer subtype adenocarcinoma (LUAD). In this study, we performed deep DNA and RNA sequencing analyses of a set of AAH, LUAD, and normal tissues. **Somatic *BRAF* variants were found in AAHs from 5 of 22 (23%) patients, 4 of 5 of whom had matched LUAD with driver *EGFR* mutations.** *KRAS* mutations were present in AAHs from 4 of 22 (18%) of patients. *KRAS* mutations in AAH were only found in ever-smokers and were

exclusive to *BRAF*-mutant cases. Integrative analysis revealed profiles expressed in *KRAS*-mutant cases (*UBE2C*, *REL*) and *BRAF*-mutant cases (*MAX*) of AAH, or common to both sets of cases (suppressed *AXL*). **Gene sets associated with suppressed antitumor (Th1; *IL12A*, *GZMB*) and elevated protumor (*CCR2*, *CTLA-4*) immune signaling were enriched in AAH development and progression.** Our results reveal potentially divergent *BRAF* or *KRAS* pathways in AAH as well as immune dysregulation in the pathogenesis of this premalignant lung lesion. *Cancer Res*; 77(22); 6119–30. ©2017 AACR.

Introduction

Non-small cell lung cancer (NSCLC) constitutes the majority (~85%) of lung malignancies (1). NSCLC is also the leading cause of cancer mortality (2). This is largely attributed to late diagnosis after locoregional or distant spread (1). Advances (e.g., molecular-based) in early detection and prevention of NSCLC have been

limited by a poor understanding of early changes in the pathogenesis of the disease (3).

NSCLC is mainly composed of two histologic subtypes, adenocarcinomas (LUAD) and squamous cell carcinomas (LUSC), with LUAD the most common of these (1). Studies have demonstrated that LUADs and LUSCs carry different genomic landscapes of driver mutations as well as disparate clinicopathologic features (3). While LUSCs are diagnosed almost exclusively in smokers, LUADs are known to develop in both smokers and nonsmokers (3). In contrast to the well-characterized histopathologic sequence of various lesions (bronchial hyperplasias, metaplasias, and dysplasias, as well as carcinomas *in situ*) associated with LUSC pathogenesis, atypical adenomatous hyperplasias (AAH) are the only known precursor (preinvasive) lesions in the development of LUAD (3, 4).

Very few molecular alterations have been described in AAHs. Mutations in *EGFR* and *KRAS* have been identified previously in AAH, showing mutual exclusivity (5). Whereas *EGFR* mutations were shown to present at similar frequencies in AAH and LUAD, *KRAS* mutations (e.g., codon 12) were demonstrated to occur more frequently in AAH compared with LUAD (5). Further, it has also been shown that *KRAS*-mutant AAHs are more prevalent in smokers while *EGFR*-mutant AAHs do not show association with smoking status (5). Loss-of-heterozygosity of chromosome arms 3p, 9p, 16p, 17q, and 17p has been shown in AAH, and in common with corresponding primary LUADs (3). **Other molecular aberrations that have been identified in AAH include overexpression of cyclin D1, survivin, ERBB2 oncoproteins, and *NKX2-1* (3).** Epigenetic modifications such as increased promoter hypermethylation of genes implicated in lung cancer (e.g., *p16*) with histologic progression from normal to AAH and finally LUAD (6), as well as DNA methylation of *CDKN2A* and *PTPRN2*,

¹Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas. ²The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, Texas. ³Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. ⁴Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. ⁵Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. ⁶Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan. ⁷Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan. ⁸Division of Pulmonology and Critical Care Medicine, University of California Los Angeles, Los Angeles, California. ⁹School of Medicine, Boston University, Boston, Massachusetts. ¹⁰Division of Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas. ¹¹Department of Biochemistry and Molecular Genetics, The American University of Beirut, Beirut, Lebanon.

Note: Supplementary data for this article are available at Cancer Research Online (<http://cancerres.aacrjournals.org/>).

P. Scheet and H. Kadara contributed equally to this article.

Correspondence Authors: Paul Scheet, Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, E-mail: pscheet@alum.wustl.edu; and Humam Kadara, Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American University of Beirut, Beirut, Lebanon, E-mail: hk94@aub.edu.lb

doi: 10.1158/0008-5472.CAN-17-1605

©2017 American Association for Cancer Research.




Figure 1.

Study design to understand the development and progression of adenomatous atypical hyperplasia. Diagnosis and histopathologic determination of specimens following H&E staining were performed to determine and classify NL, AAH, and LUAD. A two-pronged approach was used to study the pathogenesis of AAH. Deep targeted sequencing of 409 cancer-associated genes was performed to identify somatic point mutations and transcriptome sequencing was carried out to study expression profiles.

have also been reported in AAHs (7). A recent multiregion sequencing study identified several clonal events predicted to be involved in the transformation of these precursor lesions and that were further shown to be present in paired circulating DNA (8). These studies point to the molecular complexity of AAH, which is still poorly understood, and its role as a precursor to LUAD.

We interrogated, by deep sequencing, somatic mutations and gene expression changes in normal tissues, AAHs and malignant tumors from patients with LUAD. We identify subgroups of AAHs with distinct driver mutations, expression signatures and aberrant markers of the immune response that inform the molecular pathogenesis of AAH. These alterations offer a window to explore new strategies for early clinical management (e.g., detection and targeted chemoprevention) of LUAD.

Materials and Methods

Cohort of cases with AAHs

Normal lung parenchyma tissues (NL), AAHs, and lung adenocarcinomas (LUAD; $n = 67$ samples) were acquired from 22 patients with early-stage LUAD who were evaluated at the Aichi Cancer Center (Nagoya, Japan) and Nagasaki University (Nagasaki, Japan). Specimens were approved for study by Institutional Review Boards and according to the international ethical guidelines for biomedical research involving human subjects (Council

for International Organizations of Medical Sciences). Informed written consents were received from all subjects wherever necessary. Cases with available AAHs were included in the analysis to study mutational and expression signatures involved in the pathogenesis of AAH (Fig. 1). Clinicopathologic features of these patients are summarized in Table 1. The diagnosis, specimen collection and slide preparation were carried out between 2011 and 2015 for all patients. Specimens were obtained formalin-fixed and paraffin-embedded (FFPE) and stained by hematoxylin and eosin (H&E). A tabulation of cases and samples analyzed by DNA- (22 cases) and RNA- (17 cases) sequencing is provided in Supplementary Table S1.

DNA and total RNA isolation

DNA/RNA was extracted from all samples using the AllPrep DNA/RNA FFPE Kit from Qiagen and suspended in nuclease free water (RNA) or AE buffer (DNA). Sample concentrations were measured on a NanoDrop 1000 (Thermo Fisher Scientific), and RNA integrity numbers indicative of overall quality were obtained on the 2100 Bioanalyzer (Agilent Technologies) using the RNA 6000 Nano or Pico kit based on RNA concentrations and according to the manufacturer's protocol. DNA was quantified using the Quant-iT PicoGreen double-stranded DNA (dsDNA) kit (Thermo Fisher Scientific) according to the manufacturer's instructions.

Table 1. Cases studied with AAH

Case	Age, y	Gender	Tobacco history	Stage
1	70	Male	Ever	IA
2	21	Female	Ever	IB
3	67	Male	Ever	IA
4	46	Female	Ever	IA
5	79	Female	Never	IA
6	40	Male	Ever	IA
7	72	Male	Never	IA
8	48	Female	Never	IA
9	51	Female	Never	IB
10	81	Female	Never	IA
11	67	Male	Ever	IA
12	63	Female	Never	IA
13	79	Female	Ever	IA
14	54	Female	Never	IA
15	62	Male	Ever	IA
16	64	Female	Never	IA
17	67	Male	Ever	IA
18	57	Female	Never	IA
19	71	Male	Ever	IB
20	63	Male	Ever	IIIA
21	74	Female	Never	IA
22	60	Male	Ever	IA

Deep targeted DNA sequencing

The Ion AmpliSeq Comprehensive Cancer Panel (Thermo Fisher Scientific) comprising primers for 409 canonical cancer-associated genes and the AmpliSeq Library Kit 2.0 (Thermo Fisher Scientific) were used to prepare barcoded libraries from the FFPE DNA samples. Sequencing was performed on the Ion Torrent Proton platform according to the manufacturer's instructions. The targeted DNA sequencing data files have been deposited in the sequence read archive (SRA) under Bioproject accession PRJNA398260.

Identification of somatic mutations

Using BAM files generated in the Ion Torrent server, somatic variants were rigorously identified based on four different variant calling methods: the Ion Torrent proprietary software Ion Reporter, marginal VCFs generated from Torrent Variant Caller (TVC), MuTect (9) and VarScan2 (10). Instead of using all variants detected by any of the four callers, for each sample, the stringency was increased to include variants that were detected by at least two different callers, with the exception of those identified by Ion Reporter software and TVC. Variants in exonic, splicing, and untranslated regions (UTR) were assessed, focusing on exonic single-nucleotide variants within the targeted 409 cancer gene panel. Nonsynonymous mutations in genes considered to be *bona fide* drivers of cancer according to the previous report by Vogelstein and colleagues (11) were analyzed in AAHs and LUADs. Mutations in genes previously determined by The Cancer Genome Atlas (TCGA) to be significantly mutated in LUAD (12) were also assessed in both AAHs and LUADs.

Transcriptome sequencing

A subset of the cases (15 NLs, 17 AAHs, and 16 LUADs from 17 different cases) was selected for transcriptome sequencing based on specimen availability as well as on transcriptome sequencing quality indicated by percentage of mapped reads and valid on-target reads. All samples were reverse-transcribed to generate cDNA libraries using the Ion AmpliSeq Transcriptome Human Gene Expression Kit (Thermo Fisher Scientific) adhering to the

manufacturer's protocol. For sequencing, specimens from two cases were processed together in one chip. All samples were sequenced on an Ion Proton sequencer. Raw transcriptome sequence data files have been deposited in the gene expression omnibus under data series GSE102511.

Expression analysis

Transcriptomes were quantified from BAM alignment files generated in the Ion Torrent server using an expectation-maximization (E/M) algorithm based procedure (13). Resultant gene-based counts were normalized, log (base 2) transformed, and corrected for batch using the R limma package (14). Hierarchical clustering using Pearson correlation was performed in R. Pathways, gene-network identification and gene set enrichment analyses were performed using the commercially available software Ingenuity Pathways Analysis.

Additional details are found in the Supplementary Methods.

Results

Molecular profiling of normal lung tissue, AAH, and early-stage lung adenocarcinoma

There is a limited understanding of molecular alterations in AAH, the only known precursor lesion for the major lung cancer subtype adenocarcinoma (3, 4). Here, we sought to survey mutation and expression profiles in the pathogenesis of AAHs by studying these premalignant lesions along with normal tissues and primary LUADs (Fig. 1) from 22 patients with early-stage LUAD (Table 1). Diagnosis and histopathologic determination of specimens (normal lung, AAH, LUAD) were conducted by analysis of H&E staining of 5- μ m sections (Fig. 1) and according to the WHO report on lung tumor classification by Travis and colleagues (15). Among the 22 patients, 12 were ever-smokers and 10 were nonsmokers (Table 1). The cohort comprised 12 females and 10 males with a median age of 64. The majority ($n = 18$) of LUADs were stage IA with the remaining four cases determined to be IB ($n = 3$) and IIIA ($n = 1$; Table 1). We studied matched samples ($n = 67$; 1 patient comprised two tumor specimens; Supplementary Table S1) from the 22 early-stage LUAD patients by deep (mean = $961\times$) targeted sequencing of a 409 pan-cancer gene panel (Supplementary Table S2). A subset of the cases ($n = 17$) and samples ($n = 48$), based on availability and sequencing quality of AAHs, were also surveyed by transcriptome sequencing (Supplementary Table S1). Details of the quality metrics for each sequencing platform are listed in Supplementary Table S2.

Mutational landscape of AAH

All 45 AAHs and LUADs exhibited at least one somatic variant (exonic, splicing or in UTRs) with a mean of 6.1 variants (min = 1, max = 19) in AAHs and 10.6 (min = 1, max = 60) in LUADs (Supplementary Fig. S1). Nonsmokers displayed an expected lower somatic mutation burden than ever-smokers in the LUADs (5.4 vs. 14.5); however, they exhibited a similar burden in AAHs (6.4 vs. 5.9; Supplementary Fig. S2). We then specifically interrogated in AAH, nonsynonymous mutations in genes considered to be *bona fide* drivers of cancer (Fig. 2A; ref. 11). We also examined mutations in genes previously determined by TCGA to be significantly recurrently altered in LUAD (12). AAHs from 5 patients (23%) exhibited somatic activating mutations in the *BRAF* oncogene (Fig. 2A). Interestingly, the *BRAF* mutations were not detected in the paired LUAD specimens (Fig. 2A; Fig. 2B;




Figure 2.


Somatic mutation profiles in AAH. Deep targeted sequencing of a cancer gene panel ($n = 409$) and identification of somatic nonsynonymous mutations in AAHs and LUADs was performed as described in Materials and Methods. **A**, We examined, in greater detail, mutations in previously established lung cancer drivers from the TCGA (12) as well as other known cancer-associated genes (11). AAH specimens ($n = 17$) that exhibited a mutation in either driver gene set were plotted. The paired LUADs were also plotted depicting mutations in genes previously established by the TCGA to be significantly mutated in LUAD (12). Shown within the red panel is the enrichment of *EGFR* mutations in LUAD (80%) paired to *BRAF*-mutant AAH. **B**, A tissue level analysis of mutations in AAH and LUAD specimens was performed to identify mutated genes, from the same set of driver genes surveyed in **A**, that were common or disparate between AAH and LUAD. **C**, Lollipop plot for mutations (p.K601E; $n = 4$ and p.N581S; $n = 1$) in the *BRAF* gene and their prevalence in AAH specimens.

Supplementary Tables S3 and S4). Four of the five AAHs exhibited a *BRAF* p.K601E mutation, the other AAH contained a *BRAF* p.N581S variant (Fig. 2C; Supplementary Table S3). *KRAS* was the second most recurrently mutated gene in AAHs (four cases, 18%; Fig. 2A). All four *KRAS*-mutant premalignant tissues were from ever-smokers, in contrast to *BRAF*-mutant AAHs (from three nonsmokers and two ever-smokers; Fig. 2A). Also, AAH *KRAS* and *BRAF* mutations showed mutual exclusivity (Fig. 2A). An interesting observation was that for four of the five cases (80%) with *BRAF*-mutant AAHs, their paired LUADs harbored activating mutations (three p.L858R in exon 21 and one p.S752F in exon 19; Supplementary Table S3) of the *EGFR* oncogene (Fig. 2A). The other LUAD exhibited inactivating mutations in *KEAP1* and *STK11* tumor suppressors (Supplementary Table S3). LUADs of cases with the *KRAS*-mutant AAHs exhibited mutations in other drivers besides *KRAS* such as *TP53* (Fig. 2A). We further validated by digital PCR, the presence of all sequencing derived *BRAF* and *KRAS* mutations in AAHs, and the *EGFR* p.L858R mutation in both AAHs and LUADs that exhibited these patterns (Supplementary Table S5; Supplementary Fig. S3). Variant allele frequen-

cies (VAF) based on digital PCR were consistent with sequencing-based VAFs for these loci (Supplementary Table S5). *TSC1* was the most frequently mutated tumor suppressor in AAHs (13.6%; two nonsense and one missense mutation; Fig. 2A; Supplementary Table S3). We also noted other mutated oncogenes (*EGFR* and *JAK3*) and tumor suppressors (*CDKN2A* and *TP53*) in AAHs (Fig. 2A). Additionally, in this cohort, 28 genes were mutated in both AAHs and LUADs (e.g., *KRAS*, *TP53*, *KEAP1*, and *CDKN2A*), 84 were found only in LUADs (*STK11* and *PIK3CA*) and 29 were found only in the preneoplastic lesions (*AMER1*, *BRAF*, *KDM5C*, and *ERBB2*; Fig. 2B; Supplementary Table S4). Even for genes that were shared between AAH and LUAD tissues, there were notable examples of differential frequency (e.g., *KRAS* more common in AAH; *EGFR* and *TP53* more common in LUAD; Supplementary Fig. S4). On further examination of these 28 shared genes, we found that *EGFR* and *KAT6B* exhibited the same mutations in both tissues (Supplementary Table S3). There was also an enrichment of different mutations on codon 12 of *KRAS* in both the tissues (Supplementary Table S3). Our findings underscore subgroups of AAH with different mutated driver genes (*BRAF* vs.

Figure 3.

Expression profiles differentially modulated in development of AAH and lung adenocarcinoma. Transcriptome sequencing was performed as described in Materials and Methods. Genes ($n = 1008$) differentially expressed between the three tissues (AAH vs. NL, LUAD vs. NL, or LUAD vs. AAH) were determined using ANOVA ($P < 0.001$, 2-fold change) and analyzed by hierarchical clustering (red, upregulated relative to median sample; blue, downregulated relative to median sample). Genes were grouped into eight different patterns based on two one-sided t tests for NL to AAH and AAH to LUAD comparisons. Patterns of differential expression in each gene cluster are schematically depicted on the right. Pathways and gene set enrichment analysis were performed using Ingenuity Pathways Analysis. Pathways deregulated in each cluster of genes are depicted in red (activation) and blue (inhibition) alongside the heatmap. Mutations status of *EGFR*, *KRAS*, and *BRAF* for AAH and LUAD specimens is depicted below.



KRAS) suggestive of potentially various mechanisms in the pathogenesis of these premalignant lesions.

Expression profiles in the development and progression of AAH

Next, we sought to characterize expression profiles signifying the development of AAH from NL, and its progression to LUAD. We performed RNA sequencing of a subset of the cases and samples (15 NLs, 17 AAHs, and 16 LUADs—from 17 patients), based on availability and quality of AAHs, using a capture method targeting over 20,000 Refseq genes. Using an ANOVA model with tissue type (NL, AAH, and LUAD) as a factor and patient as a random effect, with a test of no expression difference ($P < 0.001$) and an observed 2-fold change minimum among pairwise tissue comparisons, we identified 1,008 genes differentially expressed in at least one of three tissue types (Fig. 3; Supplementary Table S6). Using one-sided t tests to interrogate the two-step (NL to AAH and AAH to LUAD) modes of differential expression, we identified eight patterns or clusters of expression among the identified profiles (Fig. 3). These consisted of the following: decrease ($n = 214$) from NL to AAH and from AAH to LUAD; increase ($n = 204$) from NL to AAH and from AAH to LUAD; decrease ($n = 116$) and increase ($n = 146$) from NL to AAH alone (no change from AAH to LUAD); decrease ($n = 85$) and increase ($n = 126$) from AAH to LUAD alone (no change from NL to AAH) and less prevalent forms with no net change in expression such as an increase ($n = 33$) or decrease ($n = 84$) in AAH alone relative to

other tissues (Supplementary Table S6). A pathway-based enrichment analysis was performed for genes in each cluster to infer potentially altered signaling (Fig. 3). This analysis pinpointed decreased antitumor T-helper (Th1) immunity, and conversely, increased protumor Th2-based immune response and signaling in both phases, the development of AAH from NL and their progression to LUAD. Inhibition of *IFN-γ* and *TGFβ1* signaling occurred early in AAH, when compared with NLs, and reduced surfactant protein signaling occurred thereafter in LUAD only. Pathways and gene set enrichment analysis also revealed an activation of B-cell receptor, *CSF2* (indicative of protumor immune response), *MYC*, and *ERBB2* signaling in AAH and LUAD (Fig. 3). Activation of *WNT* and β -catenin signaling as well as modulation of gene sets associated with increased immune cell (phagocytes) migration were activated in AAH relative to NL (Fig. 3). Gene sets associated with enhanced cell cycle and proliferation as well as reduced apoptosis were modulated in LUAD relative to AAH or NL.

Differential expression programs between *BRAF*- and *KRAS*-mutant AAH

We compared and contrasted gene expression among three groups of AAHs based on driver gene mutation status identified above (Fig. 2): *BRAF* mutant, *KRAS* mutant, and *BRAF*/*KRAS* wild-type (WT). Using a similar model as described above for global gene expression analysis but with a $P < 0.01$ threshold and a





Figure 4. Differential gene expression based on driver mutation status in AAH. AAHs were subgrouped based on *BRAF* and *KRAS* mutation status: *BRAF*-mutant, *KRAS*-mutant, and *BRAF/KRAS* wild-type. Genes ($n = 327$) differentially expressed between the three AAH subgroups were identified using ANOVA ($P < 0.01$, 1.5-fold change) and analyzed by hierarchical clustering (red, upregulated relative to median sample; blue, downregulated relative to median sample).

1.5 fold-change cutoff, we identified 327 differentially modulated genes between the three different groups of AAHs (Fig. 4; Supplementary Table S7). Accordingly, these gene features indeed clustered the three groups separately based on the driver mutation

status but with *BRAF*- and *KRAS*-mutant AAHs grouped closer together than with *BRAF/KRAS* WT AAHs (Fig. 4; Supplementary Table S7). Among the genes that were enriched in the *BRAF*-mutant AAHs is the cytokinesis promoting gene *KIF5C* and the cell

Figure 5.

Deregulation of immune signaling in the molecular pathogenesis of AAH. Expression profiles for an *a priori* list ($n = 730$) of immune markers from the nCounter PanCancer Immune Profiling Panel (NanoString Technologies) was compiled (see Materials and Methods) and studied to identify differentially expressed immune genes ($n = 131$; ANOVA; $P < 0.001$ and 1.5-fold change). The genes were divided into different clusters based on patterns of differential expression between NL, AAH, and LUAD derived from two one-sided *t* tests (AAH vs. NL and LUAD vs. AAH). Patterns of differential expression in each gene cluster and select immune markers are schematically depicted on the right. Immune genes present in major clusters are also depicted on the right.



proliferation promoting transcription factor (MYC Associated Factor X) *MAX*, typically associated with *MYC* oncoprotein (Fig. 4; ref. 16). On the other hand, *KRAS*-mutant AAHs displayed upregulated expression of tumor necrosis factor receptor superfamily members 9 and 10B (*TNFRSF9* and *TNFRSF10B*), the NF- κ B subunit *RELB* and the proliferation promoting ubiquitin ligase *UBE2C* (Fig. 4). Of note, both *BRAF*-mutant and *KRAS*-mutant AAHs exhibited suppressed expression of the epithelial mesenchymal transition-promoting tyrosine kinase receptor *AXL* relative to *BRAF/KRAS* WT AAHs (Fig. 4). These findings suggest shared and disparate expression programs among AAHs with activating mutations in the oncogenic GTPases *BRAF* and *KRAS*.

Profiles of immune function in the pathogenesis of AAH

Accumulating evidence suggests a pivotal role for the host immune response in the evolution of cancer as well as dynamic interplay between emerging tumor cells and immune-based expression programs (17, 18). We sought to begin to understand contextual immune marker profiles in the development and progression of AAHs. Among these profiles we identified genes with known roles in immune signaling based on an annotated and *a priori* list from the nCounter PanCancer Immune Profiling Panel (nanoString Technologies). Using a similar random effects model described above, a significance threshold $P < 0.001$ and a 1.5-fold change, we identified 131 markers of immune response that were differentially modulated among NLs, AAHs, and LUADs (Fig. 5; Supplementary Table S8). Overall, the immune markers followed similar patterns or clusters of expression described above. This analysis revealed that *IL12A*, a cytokine most notably

associated with an antitumor immune response (19), was decreased in AAHs and LUADs relative to NLs (Fig. 5; Supplementary Table S8). Conversely, the cytokines *CXCL13* and *CXCL14*, indicative of activated B-cell chemotaxis and signaling (20, 21), were upregulated in AAHs and LUADs (Fig. 5). Moreover, we found aberrant immune marker expression occurring early in AAHs, relative to NLs (Fig. 5). We found early and significantly decreased expression of prototypical markers of the antitumor immune response (e.g., *GZMB*) in AAHs relative to NLs (Fig. 5). On the other hand, AAHs exhibited increased expression of the tumor-supportive chemokine receptor *CCR2* (Fig. 5; ref. 22). Of note, we found that the major immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (*CTLA-4*; ref. 23) was significantly upregulated in LUADs relative to AAHs but not so in the premalignant lesions relative to NLs (Fig. 5; Supplementary Table S8), suggesting that aberrant immune checkpoint function by *CTLA-4* may be implicated in progression of AAH to LUAD. These findings accentuate the role of aberrant immune function and signaling early on in the development and progression of AAH.

Discussion

There is a lack of understanding of the molecular aberrations leading to the initiation as well as the progression of AAH, the only known precursor lesion to LUAD (3). Here, we probed the mutation and gene expression landscapes of AAHs in comparison with normal tissues and early-stage LUADs from the same (matched) patients. We delineated subgroups of AAHs with




Figure 6.

Proposed models for the pathogenesis of AAH. Two potential divergent modes in the pathogenesis of these preneoplastic lesions are proposed based on the mutual exclusivity of mutations and disparate expression profiles. A subgroup of AAHs, occurring in both nonsmokers and ever-smokers, was initiated by *BRAF* and tend to be associated with development of LUADs with driver mutations in the *EGFR* oncogene (not excluding the possibility that the *EGFR*-mutant LUADs may have arisen from different AAHs). Mechanisms involved in the potential progression of *BRAF*-mutant AAH to LUAD (e.g., *EGFR*-mutant tumors) warrant further studies. Another subset of AAHs is driven by *KRAS*, occurs predominantly in ever-smokers, and leads to LUADs with mutations in other driver genes besides *KRAS* (e.g., *TP53*). Transcriptome sequencing analysis pointed to aberrant immune signaling (e.g., upregulated *CTLA-4*) in the pathogenesis of AAH. Further analysis (e.g., of a larger cohort of AAH) may help underscore profiles, immune markers, and pathways unique to each molecular group of AAHs, thus paving the way for new strategies (e.g., immune-based) for (chemo)prevention and early intervention.

mutually exclusive and distinct driver gene mutation status; namely *BRAF*-mutant (both nonsmokers and ever-smokers), *KRAS*-mutant (ever-smokers only) and *KRAS/BRAF* WT AAHs. By agnostic transcriptome sequencing analysis, we also identified various patterns of expression profiles and pathways in the molecular pathogenesis of AAH. Further analysis underscored markers of immune function that are significantly differentially modulated, early on, in AAH (downregulation of *GZMB*) relative to NL as well as those deregulated in LUADs relative to AAHs (e.g., *CTLA-4*). Our study highlights early recurrent driver mutations, expression profiles, and markers of immune response in AAH that offer a window to understand the molecular pathogenesis of these premalignant lesions.

In this cohort, we found that the *BRAF* oncogene was the most commonly mutated gene in AAH (four patients with p.K601E and one with p.N581S; Supplementary Table S3) followed by *KRAS* (predominantly in codon 12). No *BRAF* variants were found in the paired LUADs. Of note, among AAHs, mutations in *BRAF* and *KRAS* were mutually exclusive. Whereas *KRAS*-mutant AAHs were from ever-smokers, *BRAF* mutations in AAHs occurred in both nonsmokers and ever-smokers. The *BRAF* p.K601E variant has been previously noted in preneoplastic melanocytic lesions and melanomas *in situ* as well as in thyroid adenomas (24–26), thus pointing to the probable role of *BRAF* in early stages of oncogenesis (i.e., development of preneoplasia such as AAH). The *BRAF* p.K601E mutation was also found in small proportions of

cancers of the thyroid, colon, and skin (27). This may suggest that an enrichment for this hotspot driver mutation highlights a crucial mechanism for AAH and LUAD pathogenesis. Indeed, studies by the TCGA (12) and our group (28) showed relatively infrequent (~3%) *BRAF* mutations in LUADs. Yet, its absence in our sample set of LUADs, including in tumor specimens from patients with *BRAF*-mutant AAH is intriguing. It cannot be neglected that this may, in part, be due to our relatively modest set of samples (further discussed below).

An intriguing finding from our study is the pattern of *BRAF* and *EGFR* mutations in the paired LUADs. In four of the five *BRAF*-mutant AAHs, the paired LUADs exhibited driver *EGFR* mutations (e.g., p.L858R). Conversely, LUADs of *KRAS*-mutant AAHs displayed several other driver mutations (*TP53*, *KRAS*) that are typically associated with smoking (3). Our study also underscores previously uncharacterized properties of these AAH *BRAF* mutations, namely mutual exclusivity with *KRAS* and correlation with smoking patterns. Based on our findings on mutual exclusivity of *BRAF* and *KRAS* in AAHs along with the disparate patterns of mutations in the paired LUADs, it is plausible to suggest that there are divergent pathways in pathogenesis of these preneoplastic lesions. A schematic of this paradigm is represented in Fig. 6. A similar divergent model to malignancy has also been recently described in the evolution of different melanoma subtypes from their precursor lesions (26).

The multiregion sequencing study by Izumchenko and colleagues (8) supports several of our findings. First, their study noted *BRAF* as the most commonly mutated gene in AAH, albeit in a smaller cohort of six patients. Further, they identified the *BRAF* p.K601E variant in a single AAH sample at a very low variant allele frequency (2%). Second, the mutual exclusivity of *BRAF* and *KRAS* mutations that we observed in AAHs can also be inferred from their data. Third, in both studies, *EGFR* and *KRAS* were the only driver genes sharing the exact mutation in both AAHs and LUADs. Fourth, among the 28 genes we found to be mutated in both AAHs and LUADs (Fig. 2B), they observed three (*TP53*, *EGFR*, and *KRAS*) to be mutated. Additionally, *APC*, *CDKN2A*, *CREBBP*, and *NF1*, which we observed as shared mutated genes were only reported in either AAHs or malignant lesions in their study. These disparities are not absolute as they may result from imperfect detection due to technological limitations (e.g., sequencing depths) and differences in study design. In comparison with their study, we surveyed a greater number of patients and genes as well as achieved a higher sequencing depth to detect potentially rare (within-sample) variants. Further, we identified recurrent *BRAF* mutations (most commonly p.K601E) that exhibited molecular (mutual exclusivity with *KRAS*) and clinicopathologic (also found in nonsmokers) features and that were present at a higher allele frequency (10%–37%; Supplementary Table S3) than observed previously. Nonetheless, given the complexity of AAHs and the malignant lesions leading to invasive LUAD, it is interesting, and indeed confirmatory, to identify similar gene mutation patterns across studies.

Complementing our DNA analysis is our agnostic transcriptome sequencing analysis that revealed differential gene expression programs that occur in different stages of LUAD pathogenesis—early in development of AAH from normal tissue, in LUADs, or in both lesion types. Gene set enrichment and pathway analysis pinpointed elevated immune cell trafficking and *WNT*/β-catenin signaling as well as an inhibition of the antitumor inflammatory response (Th1) and transforming growth factor beta 1 (*TGFB1*) signaling in development of AAH from normal lung. *WNT*/β-catenin signaling has been previously shown to be activated in progression of oral leukoplakia, a precancerous lesion of head and neck squamous cell carcinoma (29). Conversely, gene sets associated with increased cell cycle and proliferation, decreased apoptosis, and reduced function of pulmonary surfactant proteins (e.g., *SFTPs A1*, *A2*, *C*, and *D*) were enriched in profiles differentially expressed in LUAD relative to AAH. Several key signaling pathways (e.g., those mediated by *EGFR*, *MYC*, and *CSF2*) were elevated/enriched in AAH and furthermore in LUAD, consistent with their role in tumor progression (3). Increased *EGFR* was shown to promote cellular proliferation, inhibit apoptosis, and drive development and progression of bronchial dysplasia (30). Similarly, *MYC* overexpression has been previously reported in colorectal polyps with a level of expression proportional to the polyp size as well as dysplastic histology (31). By transcriptome sequencing, we also identified differentially expressed profiles between AAHs with mutations in *BRAF* and *KRAS*. *BRAF*-mutant AAHs showed significant downregulation of adenosine deaminase, an enzyme involved in nucleotide metabolism, the deficit of which may lead to impaired DNA synthesis and repair (32). In contrast, *SOS2*, an oncogene known to confer increased growth potential of tumor cells exhibiting an oncogenic *KRAS* (33), and ubiquitin conjugating enzyme E2C (*UBE2C*), previously shown to be elevated in lung cancer lesions, particularly in ever-smokers

(34), was enriched in the *KRAS*-mutant AAHs compared with *BRAF*-mutant AAHs. Taken together, these data point to early changes in the development and progression of AAH and that would thus comprise ideal targets for chemoprevention of LUAD.

Our findings on aberrant immune-regulated pathways from the agnostic gene expression analysis prompted us to more closely probe the modulation of known markers of immune function. Our immune marker profiling overall suggested an activation of protumor immune pathways (i.e., Th2) and B-cell receptor signaling as well as an inhibition of antitumor immune response (e.g., Th1-derived *IFN-γ* signaling). Similar findings have been reported in previous studies of Barrett esophageal tissues, a premalignant condition with a high risk of progression to esophageal adenocarcinomas (35). *IL12A*, known for its proinflammatory antitumor response, along with antitumor immune chemokines (e.g., *CCL3*, *CCL4*, *TLR4*) and apoptosis-inducing proteases (*GZMB*) were decreased in AAH relative to normal lung. On the other hand, we found elevated expression of the *CCL2* chemokine receptor *CCR2* in AAH relative to normal lung. *CCR2* has been shown to enhance tumor growth, angiogenesis, and tumor progression and was demonstrated to be overexpressed in several tumor tissues (22). Recently, *CCL2*/*CCR2*-based immune prevention models were shown to attenuate tumor development and metastasis (22, 36). Of note, we identified an increasing expression in chemokines *CXCL13* and *CXCL14*, both known for their role in inflammatory processes and immune response (20), and *SPPI*, previously shown to be overexpressed in premalignant lesions of the oral epithelium as well as actinic keratosis, the premalignant lesion to skin squamous cell carcinomas (37). We also found that *CD27*, which in combination with its ligand *CD70* is known to generate a potent costimulatory signal, was increased in AAH relative to normal lung. Notably, our analysis pointed to significantly increased expression of the major immune checkpoint *CTLA-4* in LUAD relative to AAH (23). We also observed disparate patterns of immune marker expression among AAHs with different recurrent mutated driver genes (*BRAF*-mutant, *KRAS*-mutant, and *BRAF*/*KRAS* WT). We noted decreased expression of *TNFRSF9*, also called *CD137*, known to regulate the activation of T cells and a promising target for enhancing antitumor immune responses (38), in *BRAF*-mutant AAHs, suggesting a relatively dampened immune response in this subgroup of AAH. Conversely, we found decreased expression of the receptor tyrosine kinase *AXL*, previously shown to promote protumor immune responses (39), in AAHs with mutations in either *BRAF* or *KRAS*. These findings, albeit based on a limited cohort of AAHs analyzed by both DNA and RNA sequencing, point to differential aberrant immune signaling among AAH based on driver mutation status. Future studies surveying a larger number of AAH have the potential to corroborate these observations. Nonetheless, we posit here that aberrant immune signaling (e.g., attenuated antitumor immune response) is a common, perhaps critical, feature of AAH and LUAD development, as illustrated in Fig. 6. Indeed, ongoing whole-exome sequencing studies have begun to shed light on neoantigen profiles in AAH (40), analogous to observations recently made for LUADs (41). Also, further studies examining protein (e.g., by multiplexed immunohistochemistry) levels of markers of various immune cell infiltrates will shed more light on the role of the immune response in the pathogenesis of AAH. It is important to mention that immune-based therapy has come to the forefront of targeted therapeutic strategies for various malignancies including those of the lung (42). For instance,

monoclonal antibodies targeting genes such as *CD27* and *CTLA-4* are already being tested for treatment of various cancers, including lung adenocarcinomas (43). In this context and as alluded to previously (44, 45), our findings suggest that targeting immune responses and signaling (e.g., immune checkpoint blockade) may be a viable strategy to prevent progression of preneoplasia such as AAH.

It is important to note that our study is not without limitations. While we comprehensively studied paired AAHs and LUADs, our cross sectional study design is not best positioned to thoroughly characterize the "progression" of AAH to LUAD. Naturally, the AAHs that already progressed to LUADs are no longer available for analysis. Our present report lends to the need for further longitudinal studies with a larger number of samples in which expression data and markers of the immune response can be aligned with time and space. Additionally, future longitudinal studies surveying AAHs in patients without overt lung malignancy may also help pinpoint drivers of AAH progression. Further, based on our findings on the absence of *BRAF* mutations in the LUADs studied in our cohort, one cannot rule out the possibility that the *BRAF*-mutant AAHs are benign and may not be the preneoplastic lesions that eventually progress to LUADs. Earlier studies have insinuated that *BRAF* mutations are important for initiation of premalignancy rather than their expansion or progression (8, 46). Lungs of mice genetically engineered to express a mutant form of *Braf* (p.V600E) were shown to develop hyperplasias that progressed to adenoma (47). Of note, only after mutations in other genes (e.g., *Tp53*) did the *Braf*-mutant lesions progress to LUAD (47). Yet, the strong pairing of *BRAF*-mutant AAHs with *EGFR*-mutant LUADs is nonetheless an interesting observation that is worth investigating in future studies comprising a larger number of patients with both AAHs and LUADs. Further, that these patterns hold across lesions arising independently, although potentially from the same cell lineage, reflect the patient-specific nature of their development and highlight the potential for personalized prevention strategies. It is also worthwhile to mention that our cohort was mainly comprised of East Asian patients. Earlier studies have demonstrated that LUADs of East Asians exhibit disparate mutational spectra (e.g., more prevalent activating mutations in *EGFR*) relative to LUADs from Western (or Caucasian) patients (48, 49). It is reasonable to surmise that mutational differences in AAHs, across patients of different ethnicities, will roughly reflect those we observe in LUADs. In this context, our results and proposed paradigm could be more relevant to the East Asian population-based on our cohort and necessitate future work in larger populations comprising diverse ethnicities. Also, recent pathological classification guidelines for LUAD have underscored subgroups with pure lepidic growth (adenocarcinoma *in situ*; AIS) and those that exhibit predominant lepidic growth and with less than 5-mm invasion (minimally invasive adenocarcinoma; MIA; ref. 3). Earlier work in East Asian LUAD patients suggested that LUADs of the "terminal respiratory unit" progress from AAH to AIS and then to invasive lesions (3). It is plausible that AIS may have distinct profiles that suggest an intermediate stage (8, 26) in the progression of AAH to LUAD. Our cohort largely comprised LUADs with very few AIS or MIA, too limited in size to further delineate profiles along this progression. Future studies are warranted to align with space mutational profiles, gene expression, and markers of the immune response, partic-

ularly those shared between AAH and LUAD, and determine their contextual role in development of AIS and their progression to LUAD. Also, indeed, recent and ongoing efforts have begun to distinguish potentially distinct profiles in the multistep progression of AAH to AIS and subsequently to LUAD (3, 8, 40).

Findings from our study shed light on some of the earliest mutation events, expression changes as well as altered immune pathways in the pathogenesis of AAH, the only known precursor lesion to LUAD. The different mechanisms in the pathogenesis of AAH we explore here may further identify novel biomarkers and potentially offer immune-based intervention or other personalized prevention in patients with early-stage LUAD. This further accentuates the need for a greater depth and understanding of immunotherapeutic strategies early on, in potentially less hostile environments such as those typified by premalignant lung lesions.

Disclosure of Potential Conflicts of Interest

J. Zhang has received honoraria from speakers bureau from BMS. J. Fukuoka is CEO of Pathology Institute Corp. A.E. Spira is a consultant/advisory board member for Janssen Pharma. E.T. Hawk has received honoraria from speakers bureau of National Cancer Institute, Huntsman Cancer Institute, American Cancer Society, University of New Mexico ECHO Advisory Group, Rice University, Mayo Clinic Cancer Center, Kansas University Medical Center, Ohio State University Comprehensive Cancer Center, Iowa Cancer Consortium, USA Mitchell Cancer Institute, Roswell Park Cancer Institute, Simmons Comprehensive Cancer Center, and University of Nebraska Medical Center, and is a consultant/advisory board member for Cancer Prevention Pharmaceuticals, PLx Pharma, and POZEN. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions

Conception and design: S. Sivakumar, J. Fujimoto, J. Fukuoka, S.M. Dubinett, I.I. Wistuba, P. Scheet, H. Kadara
Development of methodology: S. Sivakumar, T.L. McDowell, L. Xu, J. Fujimoto, J. Fukuoka, J. Fowler, I.I. Wistuba, H. Kadara
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): L. Xu, J. Fujimoto, J. Fukuoka, Y. Yatabe, I.I. Wistuba
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): S. Sivakumar, F.A. San Lucas, L. Xu, J. Zhang, J. Fowler, E.T. Hawk, P. Scheet, H. Kadara
Writing, review, and/or revision of the manuscript: S. Sivakumar, T.L. McDowell, J. Fujimoto, J. Zhang, P.A. Futreal, J. Fukuoka, S.M. Dubinett, A.E. Spira, J. Fowler, E.T. Hawk, I.I. Wistuba, P. Scheet, H. Kadara
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): T.L. McDowell, W. Lang, J. Fujimoto, J. Fukuoka
Study supervision: P. Scheet, H. Kadara

Acknowledgments

We thank Dr. Eva Szabo from the Division of Cancer Prevention at the National Cancer Institute for her insightful comments.

Grant Support

This work is supported in part by Cancer Prevention and Research Institute of Texas (CPRIT) grant RP150079 (P. Scheet and H. Kadara), NIH grant R01HG005859 (P. Scheet), and The University of Texas MD Anderson Cancer Center Core Support Grant.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received May 30, 2017; revised August 25, 2017; accepted September 22, 2017; published OnlineFirst September 26, 2017.

References

- Herbst RS, Heymach JV, Lippman SM. Lung cancer. *N Engl J Med* 2008;359:1367–1380.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. *CA Cancer J Clin* 2017;67:7–30.
- Kadara H, Scheet P, Wistuba II, Spira AE. Early Events in the molecular pathogenesis of lung cancer. *Cancer Prev Res* 2016;9:518–527.
- Mori M, Rao SK, Popper HH, Cagle PT, Fraire AE. Atypical adenomatous hyperplasia of the lung: a probable forerunner in the development of adenocarcinoma of the lung. *Mod Pathol* 2001;14:72–84.
- Sakamoto H, Shimizu J, Horio Y, Ueda R, Takahashi T, Mitsudomi T, et al. **Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas.** *J Pathol* 2007;212:287–294.
- Licchesi JDE, Westra WH, Hooker CM, Herman JG. Promoter hypermethylation of hallmark cancer genes in atypical adenomatous hyperplasia of the lung. *Clin Cancer Res* 2008;14:2570–2578.
- Selamat SA, Galler JS, Joshi AD, Fyfe MN, Campan M, Siegmund KD, et al. DNA methylation changes in atypical adenomatous hyperplasia, adenocarcinoma in situ, and lung adenocarcinoma. *PLoS One* 2011;6:e21443.
- Izumchenko E, Chang X, Brait M, Fertig E, Kagohara LT, Bedi A, et al. Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA. *Nat Commun* 2015;6:8258.
- Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. *Nat Biotechnol* 2013;31:213–219.
- Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. *Genome Res* 2012;22:568–576.
- Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer Genome Landscapes. *Science* 2013;339:1546–1558.
- Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. *Nature* 2014;511:543–550.
- Xing Y, Yu T, Wu YN, Roy M, Kim J, Lee C. An expectation-maximization algorithm for probabilistic reconstructions of full-length isoforms from splice graphs. *Nucleic Acids Res* 2006;34:3150–3160.
- Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* 2015;43:e47.
- Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. *J Thorac Oncol* 2015;10:1243–1260.
- Dang CV. MYC on the path to cancer. *Cell* 2012;149:22–35.
- Gajewski TF, Schreiber H, Fu Y-X. Innate and adaptive immune cells in the tumor microenvironment. *Nat Immunol* 2013;14:1014–1022.
- Disis ML. Immune regulation of cancer. *J Clin Orthod* 2010;28:4531–4538.
- Tugues S, Burkhard SH, Ohs I, Vrohling M, Nussbaum K, vom Berg J, et al. New insights into IL-12-mediated tumor suppression. *Cell Death Differ* 2014;22:237–246.
- Lu J, Chatterjee M, Schmid H, Beck S, Gawaz M. CXCL14 as an emerging immune and inflammatory modulator. *J Inflamm* 2016;13:1.
- Panse J, Friedrichs K, Marx A, Hildebrandt Y, Luetkens T, Barrels K, et al. Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients. *Br J Cancer* 2008;99:930–938.
- Lim SY, Yuzhalin AE, Gordon-Weeks AN, Muschel RJ. Targeting the CCL2-CCR2 signaling axis in cancer metastasis. *Oncotarget* 2016;7:28697–28710.
- Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. *Cancer Immun* 2013;13:5.
- Afkhami M, Karunamurthy A, Chiosea S, Nikiforova MN, Seethala R, Nikiforov YE, et al. Histopathologic and clinical characterization of thyroid tumors carrying the BRAF(K601E) mutation. *Thyroid* 2016;26:242–247.
- Macerola E, Torregrossa L, Ugolini C, Bakkar S, Vitti P, Fadda G, et al. BRAFK601E mutation in a follicular thyroid adenoma. *Int J Surg Pathol* 2017;106689691668808.
- Shain AH, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, et al. The genetic evolution of melanoma from precursor lesions. *N Engl J Med* 2015;373:1926–1936.
- Zheng G, Tseng L-H, Chen G, Haley L, Illei P, Gocke CD, et al. Clinical detection and categorization of uncommon and concomitant mutations involving BRAF. *BMC Cancer* 2015;15:779.
- Kadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SC, et al. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. *Ann Oncol* 2017; doi:10.1093/annonc/mdx062.
- Ishida K, Ito S, Wada N, Deguchi H, Hata T, Hosoda M, et al. Nuclear localization of beta-catenin involved in precancerous change in oral leukoplakia. *Mol Cancer* 2007;6:62.
- Merrick DT, Kittelson J, Winterhalder R, Kotantoulas G, Ingeberg S, Keith RL, et al. Analysis of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer. *Clin Cancer Res* 2006;12:2281–2288.
- Imaseki H, Hayashi H, Taira M, Ito Y, Tabata Y, Onoda S, et al. Expression of c-myc oncogene in colorectal polyps as a biological marker for monitoring malignant potential. *Cancer* 1989;64:704–709.
- Antonoli L, Blandizzi C, Pacher P, Haskó G. Immunity, inflammation and cancer: a leading role for adenosine. *Nat Rev Cancer* 2013;13:842–857.
- Jeng H-H, Taylor LJ, Bar-Sagi D. Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis. *Nat Commun* 2012;3:1168.
- Kadara H, Lacroix L, Behrens C, Solis L, Gu X, Lee JJ, et al. Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. *Cancer Prev Res* 2009;2:702–711.
- Kavanagh ME, Conroy MJ, Clarke NE, Gilmartin NT, O'Sullivan KE, Feighery R, et al. Impact of the inflammatory microenvironment on T-cell phenotype in the progression from reflux oesophagitis to Barrett oesophagus and oesophageal adenocarcinoma. *Cancer Lett* 2016;370:117–124.
- Jung H, Ertl L, Janson C, Schall T, Charo I. Abstract A107: Inhibition of CCR2 potentiates the checkpoint inhibitor immunotherapy in pancreatic cancer. *Cancer Immunology Research* 2016;4:A107–A107.
- Chang P-L, Harkins L, Hsieh Y-H, Hicks P, Sappayatosok K, Yodsanga S, et al. Osteopontin expression in normal skin and non-melanoma skin tumors. *J Histochem Cytochem* 2008;56:57.
- Yonezawa A, Dutt S, Chester C, Kim J, Kohrt HE. Boosting cancer immunotherapy with anti-CD137 antibody therapy. *Clin Cancer Res* 2015;21:3113–3120.
- Gay CM, Balaji K, Byers LA. Giving AXL the axe: targeting AXL in human malignancy. *Br J Cancer* 2017;116:415–423.
- Krysan K, Tran LM, Grimes BS, Walser TC, Wallace WD, Dubinett SM. Evaluation of progression associated neoepitopes and immune contexture in pulmonary premalignancy [abstract]. In: Proceedings of the 108th Annual Meeting of the American Association for Cancer Research; 2017 Apr 1–5; Washington, DC. Philadelphia (PA): AACR;2017. Abstract no. 1016.
- Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. *Science* 2015;348:124–128.
- Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. *Cancer Immunol Immunother* 2005;54:721–728.
- Cully M. Combinations with checkpoint inhibitors at wavefront of cancer immunotherapy. *Nat Rev Drug Discov* 2015;14:374–375.
- Spira A, Disis ML, Schiller JT, Vilar E, Rebeck TR, Bejar R, et al. Leveraging premalignant biology for immune-based cancer prevention. *Proc Natl Acad Sci U S A* 2016;113:10750–10758.
- Young MRI. Redirecting the focus of cancer immunotherapy to premalignant conditions. *Cancer Lett* 2017;391:83–88.

46. McCaskill-Stevens W, Pearson DC, Kramer BS, Ford LG, Lippman SM. Identifying and creating the next generation of community-based cancer prevention studies: summary of a National Cancer Institute think tank. *Cancer Prev Res* 2017;10:99–107.
47. Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. *Genes Dev* 2007;21:379–384.
48. Li S, Choi Y-L, Gong Z, Liu X, Lira M, Kan Z, et al. Comprehensive characterization of oncogenic drivers in Asian lung adenocarcinoma. *J Thorac Oncol* 2016;11:2129–2140.
49. Krishnan VG, Ebert PJ, Ting JC, Lim E, Wong S-S, Teo ASM, et al. Whole-genome sequencing of Asian lung cancers: second-hand smoke unlikely to be responsible for higher incidence of lung cancer among Asian never-smokers. *Cancer Res* 2014;74:6071–6081.